Associated Papers
Murine hematopoietic progenitor cell lines with erythroid and megakaryocyte potential.
Wu R et al.
Nature Communications, 2025
A microglia clonal inflammatory disorder in Alzheimer's disease.
Vicario R et al.
Elife, 2025
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Tan IL et al.
Cell Reports, 2023
A phospho-tyrosine-based signaling module using SPOP, CSK, and LYN controls TLR-induced IRF activity.
Tawaratsumida K et al.
Science Advances, 2022
Forskolin Stimulates Estrogen Receptor (ER) α Transcriptional Activity and Protects ER from Degradation by Distinct Mechanisms.
Tsai HW et al.
International Journal of Endocrinology, 2022
MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples.
Ikegami M et al.
Communications Biology, 2021
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Katzenellenbogen JA et al.
Nature Reviews. Cancer, 2018
Highly tamoxifen-inducible principal cell-specific Cre mice with complete fidelity in cell specificity and no leakiness.
Chen L et al.
American Journal of Physiology. Renal Physiology, 2018
Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene.
Sandlesh P et al.
Plos One, 2018
The driver landscape of sporadic chordoma.
Tarpey PS et al.
Nature Communications, 2017
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
Jordan VC et al.
Journal of the National Cancer Institute, 2015
Differential organ phenotypes after postnatal Igf1r gene conditional deletion induced by tamoxifen in UBC-CreERT2; Igf1r fl/fl double transgenic mice.
López IP et al.
Transgenic Research, 2015
A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor.
Uht RM et al.
Nuclear Receptor, 2004
CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators.
Kim JH et al.
Molecular Cell, 2003
Genetic dissection of p23, an Hsp90 cochaperone, reveals a distinct surface involved in estrogen receptor signaling.
Oxelmark E et al.
The Journal of Biological Chemistry, 2003
Functional mutations of estrogen receptor protein: assay for detection.
Nichols M et al.
Breast Cancer Research and Treatment, 2002
An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen.
Webb P et al.
The Journal of Biological Chemistry, 2000
Temperature dependence of estrogen binding: importance of a subzone in the ligand binding domain of a novel piscine estrogen receptor.
Tan NS et al.
Biochimica Et Biophysica Acta, 1999
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
Feil R et al.
Biochemical and Biophysical Research Communications, 1997
Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics.
Eng FC et al.
Molecular and Cellular Biology, 1997
Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation.
Aumais JP et al.
The Journal of Biological Chemistry, 1997
Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.
Pakdel F et al.
Molecular Endocrinology (baltimore, Md.), 1993
Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation.
Reese JC et al.
The Journal of Biological Chemistry, 1992
Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines.
Bergner CC et al.
Anticancer Research, 0